Edward Stanek to No-Observed-Adverse-Effect Level
This is a "connection" page, showing publications Edward Stanek has written about No-Observed-Adverse-Effect Level.
Connection Strength
0.087
-
Calabrese EJ, Staudenmayer JW, Stanek EJ. Drug development and hormesis: changing conceptual understanding of the dose response creates new challenges and opportunities for more effective drugs. Curr Opin Drug Discov Devel. 2006 Jan; 9(1):117-23.
Score: 0.065
-
Calabrese EJ, Hoffmann GR, Stanek EJ, Nascarella MA. Hormesis in high-throughput screening of antibacterial compounds in E coli. Hum Exp Toxicol. 2010 Aug; 29(8):667-77.
Score: 0.022